Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-11 (Cancelled)

12 (Currently Amended). A method for the treatment of a subject in need of treatment for hypoxia or ischemia-related disease comprising administering to said subject a therapeutically effective amount of an antagonist of a polypeptide having a sequence as set forth in SEQ ID NO:10, or an analogue thereof, in an amount sufficient to effect an inhibition or inactivation of the protein so as to thereby treat the subject.

13 (Original). The method of claim 12, wherein the hypoxia or ischemia-related disease is stroke.

14 (Previously Presented). The method of claim 12, wherein the hypoxia or ischemia-related disease is retinopathy.

15 (Previously Presented). The method of claim 12, wherein the hypoxia or ischemia-related disease is acute renal failure.

16 (Previously Presented). The method of claim 12, wherein the hypoxia or ischemia-related disease is myocardial infarction.

17 (Previously Presented). An RNA molecule which targets mRNA encoding a polypeptide having the amino acid sequence of SEQ ID NO:10.

18 (Previously Presented). The RNA molecule of claim 17 wherein the targeting prevents processing, splicing, transport or translation of the mRNA.

19 (Previously Presented). The RNA molecule of claim 17 wherein the targeting results in mRNA degradation.

20 (Previously Presented). The RNA molecule of claim 17 where the RNA is an antisense RNA.

21 (Previously Presented). The RNA molecule of claim 17 where the RNA is a ribozyme.

22 (Previously Presented). An RNA molecule which targets DNA encoding a polypeptide having the amino acid sequence of SEQ ID NO:10.

23 (Previously Presented). The RNA molecule of claim 22 wherein the targeting results in a transcriptionally inactive product.

24 (Previously Presented). A method for the treatment of a subject in need of treatment for hypoxia or ischemia-related disease comprising administering to said subject a therapeutically active amount of the RNA of claim 17.

25 (Previously Presented). A method for the treatment of a subject in need of treatment for hypoxia or ischemia -related disease comprising administering to said subject a therapeutically active amount of the RNA of claim 22.

26 (Previously Presented). The method of claim 24, wherein the hypoxia or ischemia-related disease is stroke.

27 (Previously Presented). The method of claim 24, wherein the hypoxia or ischemia-related disease is retinopathy.

28 (Previously Presented). The method of claim 24, wherein the hypoxia or ischemia-related disease is acute renal failure.

29 (Previously Presented). The method of claim 24, wherein the hypoxia or ischemia-related disease is myocardial infarction.

30 (Previously Presented). The method of claim 25, wherein the hypoxia or ischemia-related disease is stroke.

31 (Previously Presented). The method of claim 25, wherein the hypoxia or ischemia-related disease is retinopathy.

32 (Previously Presented). The method of claim 25, wherein the hypoxia or ischemia-related disease is acute renal failure.

33 (Currently amended). The method of claim 25, wherein the hypoxia or ischemia-related disease is myocardial infarction.

34 (New). The method of claim 12, wherein said antagonist is an antibody that specifically binds to said polypeptide.

35 (New). The method of claim 12, wherein said antagonist is an RNA molecule which targets mRNA encoding said polypeptide.

36 (New). The method of claim 35, wherein said RNA molecule comprises an antisense RNA.

37 (New). The method of claim 35, wherein said RNA molecule is a ribozyme.

38 (New). The method of claim 24, wherein said RNA comprises an antisense RNA.

39 (New). The method of claim 24, wherein said RNA is a ribozyme.